Full title: Comparing the Value of Left Atrial Strain and HFA-PEFF Score in Diagnosing Heart Failure with Preserved Ejection Fraction in Vietnamese Population: A Cross-Sectional Study

Short Title: Left Atrial Strain in Heart Failure With Preserved Ejection Fraction

1 Hai Dang Nguyen Ngoc[1¶], Thang Viet Luong[2¶], Bang Hai Ho[2], Tien Anh
2 Hoang[2*]

3 [1]The Faculty of Medicine, Duy Tan University, Da Nang, Viet Nam

4 [2]Department of Internal Medicine, Hue University of Medicine and Pharmacy,
5 Hue, Viet Nam

6 *Corresponding author:

7 Email: hatien@huemed-univ.edu.vn or hatien@hueuni.edu.vn

8 ¶Hai Nguyen Ngoc Dang and Thang Viet Luong contributed equally to this work.

9 Author contributions:

10 Hai Nguyen Ngoc Dang: Conceptualization, Methodology, Acquisition,
11 Investigation, Data curation, Writing – original draft, Writing – review &

editing.

Thang Viet Luong: Conceptualization, Methodology, Acquisition, Investigation, Data curation, Writing – original draft, Writing – review & editing.

Bang Hai Ho: Conceptualization, Acquisition, Writing – original draft.

Tien Anh Hoang: Conceptualization, Acquisition, Writing – original draft.

All authors have read and agreed to the published version of the manuscript.

Abstract

Background: Heart failure with preserved ejection fraction (HFpEF) has a high hospitalization rate. While recent guidelines recommend specific parameters like E/e', e' velocity, and left atrial volume index (LAVI) for diagnosing HFpEF, their clinical accuracy remains limited. Left atrial (LA) strain has emerged as a potential diagnostic parameter, yet its role in the Vietnamese population is unclear. This study aims to evaluate LA strain's diagnostic role in HFpEF among Vietnamese patients, exploring its relationship with established parameters of left ventricle (LV) diastolic function to determine its potential utility as a diagnostic tool.

Methods: A cross-sectional study was conducted from 15/04/2022 to 01/12/2023, involving 118 subjects, including 49 patients with HFpEF and 69 individuals without cardiac dysfunction. The study subjects were evaluated for LA strain and HFA-PEFF.

Results: LA strain including LA reservoir (LASr), conduit (LAScd), and contractile (LASct) function, in the HFpEF group were 19.97% ± 9.18%, 9.08% ± 6.18%, and 10.89% ± 5.16%, respectively. The control group had corresponding LASr, LAScd, and LASct values of 34.70% ± 5.38%, 17.33% ± 5.72%, and 17.38% ± 4.41% ($p < 0.001$). The area under the curve (AUC) for LASr, LAScd, LAScr, HFA-PEFF, LAVI, and GLS to diagnose HFpEF was 0.877, 0.836, 0.749, 0.975, 0.587, and 0.717, respectively. Comparing the AUCs for diagnosing HFpEF between LASr and HFA-PEFF, no difference was found with $p = 0.062$.

Conclusion: LA strain has a diagnostic value equivalent to the HFA-PEFF score in diagnosing HFpEF. These indices could be incorporated into the existing guidelines to enhance the diagnosis of HFpEF.

Key words: Speckle tracking echocardiography, left atrial, strain, heart failure, left ventricular ejection fraction

Introduction

Heart failure with preserved ejection fraction (HFpEF) is defined as heart failure with an ejection fraction of 50% or higher at diagnosis, affecting approximately 32 million people worldwide. Patients with HFpEF are hospitalized about 1.4 times per year and have an annual mortality rate of around 15% [1]. Left ventricular (LV) diastolic dysfunction plays a fundamental role, overarching in the pathophysiology of HFpEF [2].

The recent recommendations of the American Society of Echocardiography/European Society of Cardiovascular Imaging in 2016 use parameters such as E/e', septal e' velocity, lateral e' velocity, maximum tricuspid valve regurgitation flow (TRV) and left atrial volume index (LAVI) to evaluate LV diastolic dysfunction as well as to diagnose HFpEF [3]. However, in clinical practice, the recommendations parameters have limited precision in diagnosing HFpEF [4].

The assessment of left atrial (LA) function has recently gained prominence as a critical parameter in cardiac evaluation [5]. The LA function encompasses three primary aspects: blood storage (reservoir function), blood conduction (conduit function), and ejection function (contractile function) [6]. Commonly used indices to assess LA function include LAVI and LA size. Increased LAVI is associated with prolonged chronic LV/LA pressure overload. However, LA size takes time to change, often significantly dilating in later stages, making LAVI less sensitive in the early stages [7].

LA strain is a novel echocardiographic technique that comprehensively evaluates reservoir, conduit, and contractile functions. This method proves particularly valuable when changes are subtle and challenging to detect using conventional parameters such as LA dimensions and LAVI [8]. While LA dimensions have been previously utilized, the role of LA function as a biomarker is increasingly under evaluation, both independently and in conjunction with LA size. LA strain serves as a tool to assess LA function and can be measured

75 throughout the cardiac cycle, enabling a comprehensive evaluation of LA reservoir,
76 conduit, and contractile functions [7]. Additionally, LA strain offers the advantage
77 of being a technique mostly independent of angle and less susceptible to influences
78 from mitral annulus calcification and bundle branch block effects [9].

79 Notably, impaired LA strain has been observed in HFpEF patients, indicating
80 its potential diagnostic value [10–12]. Studies conducted in the United Kingdom
81 and China have demonstrated the utility of LA strain in assessing and diagnosing
82 HFpEF [9,13]. However, its role in the Vietnamese population remains unexplored.
83 Therefore, this study aims to evaluate the diagnostic role of LA strain in HFpEF
84 among Vietnamese individuals, contributing to a deeper understanding of its
85 applicability in clinical practice.

86 Materials and methods

87 Ethics approval statement

88 The study received approval from The Institutional Ethics Committee of Hue
89 University of Medicine and Pharmacy (Approval number: H2022/034) and adhered
90 to the Strengthening the Reporting of Observational Studies in Epidemiology
91 (STROBE) reporting guideline, conducted under the principles outlined in the
92 Declaration of Helsinki 2013. Prior to participation, written informed consent was
93 obtained from each patient or their legal representative.

94 Study population

During the period from 15/04/2022 to 01/12/2023, a cross-sectional study was undertaken. The study population consisted of adults aged 18 and above, who provided informed consent prior to their inclusion. A total of 118 subjects were recruited, comprising 49 individuals diagnosed with HFpEF (Heart Failure with preserved Ejection Fraction) in the disease group, and 69 individuals without cardiac dysfunction in the control group. These participants sought examination and treatment at Hue University Hospital within the aforementioned timeframe. Patients with HFpEF are evaluated according to the standards of AHA/ACC/HFSA in 2022 [4]: (1) Symptoms of heart failure (pulmonary congestion or systemic congestion); (2) Normal LV ejection fraction LVEF ≥ 50%; (3) Objective evidence of structural and/or functional cardiac abnormalities consistent with LV diastolic dysfunction; (4) NT-proBNP ≥ 125 pg/mL. The four recommended variables for identifying diastolic dysfunction and their abnormal cutoff values are septal $e' < 7$ cm/s or lateral $e' < 10$ cm/s, average E/e' ratio > 14, LAVI > 34 mL/m^2, and TRV > 2.8 m/s. LV diastolic dysfunction was considered present if more than half of the available parameters met these cutoff values. In cases where half of the parameters met the cutoff values (indeterminate), diastolic dysfunction was assumed to be present if patients had E/A > 2.0 or if ≥ 2 of the three parameters (E/e' ratio, TRV, and LAVI) met the cutoff values [14]. Exclusion criteria included patients who declined participation, severe valvular heart disease, heart failure with EF < 50%, and arrhythmias. Patients with unclear echocardiography images or images lacking clear visualization of the myocardial endocardial layer were also excluded. The

control group comprised 69 healthy adults undergoing health screening with no history of heart failure.

Clinical data collection, laboratory tests, and transthoracic echocardiogram

The clinical data collected included personal and family medical histories, as well as clinical variables obtained through direct interviews and medical records. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) levels were measured using a Cobas 8000 analyzer.

The echocardiographic procedure followed the guidelines of the American Society of Echocardiography for performing a comprehensive transthoracic echocardiographic examination in adults. The machine recorded the electrocardiogram alongside the echocardiographic images during the echocardiography procedure. All echocardiograms included in the final data analysis were performed on patients with normal sinus rhythm [15].

Left atrial and left ventricular strain analysis

Echocardiography images in DICOM format, meeting acceptable image quality standards, were uploaded to Philips QLAB Cardiovascular ultrasound quantification software Cardiac Analysis version 15. LA strain assessment was conducted in both the two-chamber and four-chamber views, with reference points set at the onset of the P wave in the cardiac cycle. Measurements of LA strain were

137 acquired during the reservoir, conduit, and contractile phases of LA function,
138 designated as LA strain reservoir function (LASr), LA strain conduit function
139 (LAScd), and LA strain contractile function (LASct), respectively. For LV strain
140 analysis, endocardial borders were traced on the end-systolic frame in three apical
141 views (4-chamber, 2-chamber, and 3-chamber), with end-systole defined by the
142 QRS complex or as the smallest LV volume during the cardiac cycle. The software
143 tracked speckles along the endocardial border and myocardium throughout the
144 cardiac cycle, automatically computing peak longitudinal strain and generating
145 regional data from six segments, as well as an average value for each view. For
146 patients in sinus rhythm, analyses were performed on a single cardiac cycle; for
147 those in atrial fibrillation, strain values were calculated as the average of three
148 cardiac cycles [16]. All strain measurements were performed by one strain
149 specialist in the core laboratory who was blinded to the patients' other data.

150 Results of LV and LA strain are conventionally represented as negative
151 values. However, for convenience in analysis and display, we utilized the absolute
152 values of these results. The detailed methodology is illustrated in **Fig 1**.

153 **Fig 1. Parameters of LA strain on speckle tracking echocardiography.** LASr
154 (Reservoir) in red, LAScd (Conduit) in green, and LASct (Contractile) in yellow.
155 LAScd: left atrial conduit function; LASct: left atrial contractile function; LASr:
156 left atrial reservoir function.

157 **Calculation of the Heart Failure Association-PEFF Score**

158 The Heart Failure Association-PEFF (HFA-PEFF) score comprises
159 functional, morphological, and biomarker domains (**Supplementary**). A patient
160 can score zero, minor (1 point), or major (2 points) for each domain, and then those
161 subscores are summed to produce a total score that ranges from 0 to 6 points. The
162 total score is classified as low likelihood (0 – 1 point), intermediate likelihood (2 –
163 4 points), and high likelihood (5 – 6 points) [17].

164 **Statistics**

165 All statistical analyses were conducted using SPSS Version 26 (IBM, New
166 York, United States), MedCalc Software Version 22.019 (MedCalc Software,
167 Ostend, Belgium), and GraphPad Prism Version 10 (GraphPad Software, Boston,
168 United States). Continuous variables were presented as mean ± standard deviation
169 for normally distributed variables, as determined by the Kolmogorov-Smirnov test
170 and the Shapiro-Wilk test. Non-normally distributed variables were expressed as
171 median values with interquartile ranges (25th-75th percentile). Categorical
172 variables were reported as frequencies and percentages. Intergroup differences in
173 categorical variables were assessed using Fisher's exact test, while differences in
174 continuous variables were analyzed using the unpaired T-test or the Mann-Whitney
175 U test, as appropriate.

176 Missing data were excluded from the analyses. Pearson's correlation
177 coefficient (r) and its corresponding p-value were calculated to elucidate the
178 correlation between continuous variables. The area under the curve (AUC) was

179 determined using the Wilson/Brown method to predict HFpEF. AUC comparison
180 was conducted to assess the diagnostic value of strain compared to existing
181 guideline criteria, employing the DeLong method [18]. All statistical tests were
182 two-sided, with a P-value of < 0.05 considered significant.

183 Results

184 The study was conducted on 118 subjects, of whom 49 patients with HFpEF
185 and 69 people qualified as the control group, meeting the disease selection criteria
186 according to the research criteria. Our research obtained the following results:

187 **Table 1** displays the mean age of the HFpEF and control groups as 71.45 ±
188 13.92 and 60.39 ± 6.58, respectively. The average body mass index (BMI) for the
189 case and control group was 21.92 ± 2.03 kg/m^2 and 21.71 ± 3.54 kg/m^2. The results
190 indicated no statistically significant differences in BMI between the two study
191 groups (p > 0.05). The NT-proBNP concentration in the HFpEF group exhibited a
192 non-normal distribution, with a median of 663.20 pg/mL (Quartile: 286.55 pg/mL
193 – 1417.00 pg/mL).

194 **Table 1. General Characteristics of Study Subjects.**

Characteristics	**Control group (n = 69)**	**HFpEF group (n = 49)**	**p-value**
Baseline demographic and clinical features			
Age (years)	60.39 ± 6.58	71.45 ± 13.92	< 0.001

Female	37 (53.62)	27 (55.10)	0.512
BSA (m^2)	1.55 ± 0.13	1.52 ± 0.16	0.357
BMI (kg/m^2)	21.92 ± 2.03	21.71 ± 3.54	0.710
Heart rate (bpm)	74.94 ± 10.92	80.47 ± 15.11	0.032
SBP (mmHg)	121.09 ± 8.17	130.43 ± 13.94	< 0.001
DBP (mmHg)	74.49 ± 7.48	76.10 ± 9.08	0.295
Hypertension	0	26 (53.06)	< 0.001
Diabetes	0	8 (16.33)	< 0.001
Coronary disease	0	29 (59.18)	< 0.001
NT-ProBNP (pg/mL)	64.00 [43.50 - 77.95]	663.20 [286.55 - 1417.00]	< 0.001
Left ventricular structure and function			
LVMI (g/m^2)	96.75 ± 24.48	130.45 ± 35.66	< 0.001
LVIDd (cm)	4.61 ± 0.48	5.02 ± 0.68	0.001
LVIDs (cm)	2.77 ± 0.38	3.29 ± 0.63	< 0.001
IVSd (cm)	0.94 ± 0.15	1.07 ± 0.19	< 0.001
IVSs (cm)	1.28 ± 0.15	1.41 ± 0.20	< 0.001
LVPWd (cm)	0.92 ± 0.14	0.99 ± 0.20	0.023
LVPWs (cm)	1.37 ± 0.15	1.46 ± 0.21	0.013
RWT	0.400 ± 0.067	0.403 ± 0.098	0.891
LV EF (%)	70.22 ± 6.38	63.38 ± 8.22	< 0.001
FS (%)	39.90 ± 5.22	35.27 ± 6.68	< 0.001

LV GLS (%)	20.67 ± 2.44	15.95 ± 4.76	< 0.001
Doppler echocardiography			
E velocity (cm/s)	65.61 ± 14.21	84.52 ± 25.12	0.001
A velocity (cm/s)	80.86 ± 14.34	93.79 ± 30.71	0.041
e' septal velocity (cm/s)	7.35 [6.29 - 7.93]	6 [4.57 - 7.38]	0.003
e' lateral velocity (cm/s)	8.80 [8.10 - 10.70]	7.11 [5.32 - 9.38]	0.008
E/A ratio	0.78 [0.69 - 0.93]	0.87 [0.65 - 1.24]	0.249
Average E/e ratio	7.96 ± 1.98	13.15 ± 8.12	0.002
TRV (cm/s)	129.45 ± 44.43	244.73 ± 115.50	< 0.001
Left atrial structure and function			
LAd (cm)	3.07 ± 0.48	3.55 ± 0.62	< 0.001
LAVI (mL/m^2)	18.30 [16.70 - 22.15]	24.00 [16.65 - 33.50]	0.002
LASr (%)	34.70 ± 5.38	19.97 ± 9.18	< 0.001
LASct (%)	17.33 ± 5.72	9.08 ± 6,18	< 0.001
LAScd (%)	17.38 ± 4.41	10.89 ± 5.16	< 0.001
LASr/LAVI	1.89 ± 0.53	0.95 ± 0.89	< 0.001
LASr/E/e'	4.71 ± 1.42	2.13 ± 1.29	< 0.001
HFA-PEFF score			
HFA-PEFF score	2 [2 – 3]	4 [3 – 5]	<0.001

195 Values are presented as mean ± standard deviation or number (%) or median [IQR,

196 25th-75th percentile]. A: A-wave velocity; BMI: body mass index; BSA: body
197 surface area; DBP: diastolic blood pressure; E: E-wave velocity; e': e'-wave
198 velocity; HFA-PEFF: Heart Failure Association-PEFF; IVSd: interventricular
199 septum thickness in diastole; IVSs: interventricular septum thickness in systole;
200 Lad: left atrial diameter; LAScd: left atrial conduit function; LASct: left atrial
201 contractile function; LASr: left atrial reservoir function; LAVI: left atrial volume
202 index; LV EF: left ventricular ejection fraction; LV GLS: left ventricular global
203 longitudinal strain; LVMI: left ventricular mass index; LVIDd: left ventricular
204 internal diameter in diastole; LVIDs: left ventricular internal diameter in systole;
205 LVPWd: left ventricular posterior wall thickness in diastole; LVPWs: left
206 ventricular posterior wall thickness in systole; NT-proBNP: N-terminal pro-B-type
207 natriuretic peptide; RWT: relative wall thickness; SBP: systolic blood pressure;
208 TRV: tricuspid regurgitation velocity.

209 Additionally, LV structural and functional indices, including LVMI, RWT, and
210 LV EF of the HFpEF group were 130.45 ± 35.66 g/m^2, 0.403 ± 0.098, and 63.38 ±
211 8.22%, respectively; while those of the control group were 96.75 ± 24.48 g/m^2,
212 0.400 ± 0.067, and 70.22 ± 6.38%, respectively. On echocardiography, LA strain
213 indices in the HFpEF group were lower than in the control group, with all differences
214 being statistically significant (< 0.001). Further details are illustrated in **Table 1** and
215 **Fig 2**.

216 **Fig 2. The HFA-PEFF score, LASr, LAScd, and LASct of both HFpEF and**
217 **control groups.** LA functional indices including LASr, LAScd, and LASct in the

218 control group are higher than those in the HFpEF group. Additionally, HFpEF
219 patients exhibit higher HFA-PEFF scores with a median of 4. HFA-PEFF: Heart
220 Failure Association-PEFF; LAScd: left atrial conduit function; LASct: left atrial
221 contractile function; LASr: left atrial reservoir function; ***$p < 0.001$.

222 Additionally, **Fig 3** depicts the correlation between echocardiography
223 indices, NT-proBNP, and HFA-PEFF. LASr, LAScd, and LASct showed an inverse
224 correlation with HFA-PEFF score and NT-proBNP, while also correlating with
225 measured indices of cardiac function. Detailed parameters are demonstrated in **Fig**
226 **3**.

227 **Fig 3. Heatmap depicts the correlation between echocardiography indices, NT-**
228 **ProBNP, and HFA-PEFF.** A: A-wave velocity; E: E-wave velocity; e': e'-wave
229 velocity; HFA-PEFF: Heart Failure Association-PEFF; LAScd: left atrial conduit
230 function; LASct: left atrial contractile function; LASr: left atrial reservoir function;
231 LAVI: left atrial volume index; LV GLS: left ventricular global longitudinal strain;
232 NT-proBNP: N-terminal pro-B-type natriuretic peptide; TRV: tricuspid
233 regurgitation velocity.

234 **Table 2** and **Fig 4** illustrate that the indices LASr (AUC = 0.877), LAScd
235 (AUC = 0.836), LASct (AUC = 0.749), HFA-PEFF score (AUC = 0.975) exhibit
236 high accuracy in diagnosing HFpEF. The cutoff points, sensitivity, and specificity
237 of LASr are 29.93%, 82.61%, and 91.38%, respectively. Further detailed
238 information is presented in **Table 2** and **Fig 4**.

239 **Table 2. The performance of the LA strain parameters and existing criteria to**

240 **discriminate HfpEF.**

Parameters	AUC	95%Cl		p-value	Cut-off point	Sensitivity (%)	Specificity (%)
LAVI (mL/m^2)	0.587	0.440	0.734	0.224	34	17.39	100.00
Average E/e'	0.578	0.432	0.724	0.274	14	17.39	98.26
Septal e' velocity (cm/s)	0.615	0.478	0.751	0.109	7	60.87	62.07
TRVmax (m/s)	0.565	0.419	0.711	0.362	2.8	13.04	100.00
LV GLS (%)	0.717	0.576	0.836	< 0.001	16	43.48	100.00
LASr (%)	0.877	0.776	0.979	< 0.001	29.93	82.61	91.38
LAScd (%)	0.836	0.723	0.949	< 0.001	11.63	69.57	91.38
LASct (%)	0.749	0.618	0.880	0.001	12.35	56.52	87.93
HFA-PEFF	0.975	0.942	1.000	< 0.001	5	56.52	100.00
LASr/LAVI	0.850	0.736	0.965	< 0.001	1.23	69.57	96.55
LASr/E/e'	0.894	0.809	0.978	< 0.001	3.12	82.61	89.66

241 E: E-wave velocity; e’: e’-wave velocity; HFA-PEFF: Heart Failure Association-

242 PEFF; LAScd: left atrial conduit function; LASct: left atrial contractile function;

LASr: left atrial reservoir function; LAVI: left atrial volume index; LV GLS: left ventricular global longitudinal strain; TRV: tricuspid regurgitation velocity.

Fig 4. Receiver operating characteristic curves for predicting HFpEF. E: E-wave velocity; e': e'-wave velocity; HFA-PEFF: Heart Failure Association-PEFF; LAScd: left atrial conduit function; LASct: left atrial contractile function; LASr: left atrial reservoir function; LAVI: left atrial volume index; TRV: tricuspid regurgitation velocity.

Fig 5 illustrates the area under the ROC curve for diagnosing HFpEF of HFA-PEFF and LASr, showing no difference ($p = 0.062$). Furthermore, the AUC of conventional echocardiographic indices (LAVI, E/e', e', TRV) with HFA-PEFF and LASr differed significantly with $p < 0.001$.

Fig 5. Comparison of the AUC values of LASr, HFA-PEFF score, and existing parameters in predicting HFpEF. The analysis reveals no significant difference in diagnostic value between LASr and HFA-PEFF score ($p > 0.05$). However, significant disparities were observed between LASr and LAVI, E/e', and between HFA-PEFF score and LAVI, E/e', TRV, and e' ($p < 0.05$). E: E-wave velocity; e': e'-wave velocity; HFA-PEFF: Heart Failure Association-PEFF; LASr: left atrial reservoir function; LAVI: left atrial volume index; TRV: tricuspid regurgitation velocity.

Discussion

263 In this study, we examined 118 subjects to evaluate the role of LA strain in
264 diagnosing HFpEF.

265 LA function indices such as LASr, LAScd, and LASct decreased significantly
266 in the HFpEF group compared to the control group, with a p-value < 0.001. This
267 finding is consistent with Aung et al.'s (2017) study on 83 patients, which also
268 reported decreased LASr and LASct in the HFpEF group compared to the control
269 group [19]. Similar results were observed in several other studies where LASr,
270 LAScd, and LASct were all reduced in HFpEF patients compared to the control
271 group [9,13,20,21]. Therefore, our study confirms a significant decline in LA
272 function in the HFpEF group compared to healthy subjects. Reddy et al. also
273 highlighted the important role of the LA in the progression of HFpEF. They
274 suggested that LA strain reflects the overall LA function, which progressively
275 deteriorates in the presence of chronic LV diastolic dysfunction, such as in patients
276 with HFpEF [9].

277 The American Echocardiography Association and the European Association
278 of Cardiovascular Imaging (ASE/EACVI) recommend using echocardiography to
279 diagnose HFpEF in patients with sinus rhythm using E/A ratio, LAVI, TRV, and
280 E/e' [3]. The ESC guidelines for the diagnosis of HFpEF are based on evidence of
281 functional and structural alterations of the heart using the parameters E/e', LVM,
282 LAVI, septal e' velocity, and lateral e' velocity [14]. However, these classic
283 indicators still have many limitations, and many clinical practice cases encounter
284 difficulties when the diagnosis falls into the "undetermined" state, when Doppler

measurements cannot be made, such as tachycardia or severe mitral valve disease [22]. Compared with Doppler echocardiography, the advantage of speckle tracking echocardiography when compared to conventional echocardiography is that it is independent of angle and less affected by mitral valve disease. On the other hand, the LA strain evaluates the function of the LA throughout the entire cardiac cycle rather than the functional state of a certain time point in the cardiac cycle [11]. In our study, LA strain indices including LASr (AUC = 0.877), LAScd (AUC = 0.836), and LASct (AUC = 0.749) have high values in diagnosing HFpEF equivalent to the score HFA-PEFF (AUC = 0.975). At the same time, the ability of LASr to diagnose HFpEF was superior to the LAVI (AUC = 0.670), E/e' (AUC = 0.578), septal e' velocity (AUC = 0.615), and TRV (AUC = 0.565) with $p < 0.05$. Many studies have also shown the superiority of LA strain indices in the ability to diagnose HFpEF compared to commonly used classical indices [9,23,24].

HFA-PEFF is a widely used scoring system for diagnosing HFpEF. However, evaluating this HFA-PEFF is a widely used scoring system for diagnosing HFpEF. However, evaluating this scoring system requires numerous parameters, including echocardiography, NT-proBNP, and atrial fibrillation diagnosis [17,25]. Through our study, LA strain indices have demonstrated an AUC equivalent to that of the HFA-PEFF score. When comparing the AUC of LASr and HFA-PEFF, our study found no significant difference in the HFpEF diagnostic value of LASr and HFA-PEFF score with $p = 0.062$. The 5-point HFA-PEFF score has 100% specificity, however, the sensitivity is low at only 56.52%, which can cause difficulties in

307 applying this score in clinical practice.

308 In conclusion, LA parameters on speckle tracking echocardiography may be
309 useful in diagnosing HFpEF and integration into the 2016 EACVI/ASE criteria will
310 improve diagnostic effectiveness with accuracy not inferior to conventional
311 echocardiographic parameters for diagnosing HFpEF.

312 Limitations of the study

313 Our study only compares non-invasive indices in diagnosing HFpEF and
314 does not utilize invasive interventions for evaluation or comparison with other
315 invasive indices. We only used one software for strain analysis and did not compare
316 different software programs. Furthermore, although our sample size is larger than
317 some studies, it is still relatively small, necessitating larger studies to establish
318 cutoff points applicable to clinical central Vietnam and was conducted at a single
319 location, which may limit the generalizability of the findings to other populations
320 or settings. Different populations or geographical locations may exhibit variations
321 in disease prevalence and characteristics, potentially affecting the study outcomes.
322 During sample collection, technical limitations of Doppler echocardiography may
323 have prevented us from obtaining all possible Doppler echocardiography indices
324 for comparison with LA strain indices. This study only focused on sinus rhythm
325 subjects; however, atrial fibrillation is a significant risk factor for HFpEF,
326 necessitating further research to assess the best way to combine LA strain
327 parameters with conventional parameters to determine HFpEF.

Conclusions

LA strain has a diagnostic value equivalent to the HFA-PEFF score in diagnosing HFpEF. These indices could be incorporated into the existing guidelines to enhance the diagnosis of HFpEF.

Acknowledgements

Nil

References

1. Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329: 827. doi:10.1001/jama.2023.2020

2. Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction. JACC: Cardiovascular Imaging. 2020;13: 245–257. doi:10.1016/j.jcmg.2018.12.034

3. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2016;29: 277–314. doi:10.1016/j.echo.2016.01.011

346 4. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al.
347 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. Journal
348 of Cardiac Failure. 2022;28: e1–e167. doi:10.1016/j.cardfail.2022.02.010

349 5. Boe E, Smiseth OA. Left atrial strain imaging: ready for clinical implementation
350 in heart failure with preserved ejection fraction. European Heart Journal -
351 Cardiovascular Imaging. 2022;23: 1169–1170. doi:10.1093/ehjci/jeac059

352 6. Rosca M, Lancellotti P, Popescu BA, Pierard LA. Left atrial function:
353 pathophysiology, echocardiographic assessment, and clinical applications.
354 Heart. 2011;97: 1982–1989. doi:10.1136/heartjnl-2011-300069

355 7. Gan GCH, Ferkh A, Boyd A, Thomas L. Left atrial function: evaluation by strain
356 analysis. Cardiovasc Diagn Ther. 2018;8: 29–46. doi:10.21037/cdt.2017.06.08

357 8. Jarasunas J, Aidietis A, Aidietiene S. Left atrial strain - an early marker of left
358 ventricular diastolic dysfunction in patients with hypertension and paroxysmal
359 atrial fibrillation. Cardiovasc Ultrasound. 2018;16: 29. doi:10.1186/s12947-018-
360 0147-6

361 9. Reddy YNV, Obokata M, Egbe A, Yang JH, Pislaru S, Lin G, et al. Left atrial
362 strain and compliance in the diagnostic evaluation of heart failure with preserved
363 ejection fraction. European J of Heart Fail. 2019;21: 891–900.
364 doi:10.1002/ejhf.1464

365 10. Brand A, Romero Dorta E, Wolf A, Blaschke-Waluga D, Seeland U, Crayen C,
366 et al. Phasic left atrial strain to predict worsening of diastolic function: Results
367 from the prospective Berlin Female Risk Evaluation follow-up trial. Front
368 Cardiovasc Med. 2023;10: 1070450. doi:10.3389/fcvm.2023.1070450

369 11. Ma C, Liao Y, Fan J, Zhao X, Su B, Zhou B. The novel left atrial strain
370 parameters in diagnosing of heart failure with preserved ejection fraction.
371 Echocardiography. 2022;39: 416–425. doi:10.1111/echo.15304

372 12. Kim D, Seo JH, Choi KH, Lee SH, Choi J-O, Jeon E-S, et al. Prognostic
373 Implications of Left Atrial Stiffness Index in Heart Failure Patients With
374 Preserved Ejection Fraction. JACC: Cardiovascular Imaging. 2023;16: 435–445.
375 doi:10.1016/j.jcmg.2022.11.002

376 13. Rimbas RC, Visoiu IS, Magda SL, Mihaila-Baldea S, Luchian ML, Chitroceanu
377 AM, et al. New insights into the potential utility of the left atrial function analysis
378 in heart failure with preserved ejection fraction diagnosis. Johnson DM, editor.
379 PLoS ONE. 2022;17: e0267962. doi:10.1371/journal.pone.0267962

380 14. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.
381 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
382 failure: The Task Force for the diagnosis and treatment of acute and chronic heart
383 failure of the European Society of Cardiology (ESC). Developed with the special
384 contribution of the Heart Failure Association (HFA) of the ESC. European J of
385 Heart Fail. 2016;18: 891–975. doi:10.1002/ejhf.592

386 15. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al.
387 Guidelines for Performing a Comprehensive Transthoracic Echocardiographic
388 Examination in Adults: Recommendations from the American Society of
389 Echocardiography. Journal of the American Society of Echocardiography.
390 2019;32: 1–64. doi:10.1016/j.echo.2018.06.004

391 16. Park JJ, Hwang I, Kang S, Park J, Park J, Cho G. Myocardial strain for heart
392 failure with preserved ejection fraction but without diastolic dysfunction. ESC
393 Heart Failure. 2022;9: 3308–3316. doi:10.1002/ehf2.14078

394 17. Pieske B, Tschöpe C, De Boer RA, Fraser AG, Anker SD, Donal E, et al. How
395 to diagnose heart failure with preserved ejection fraction: the HFA–PEFF
396 diagnostic algorithm: a consensus recommendation from the Heart Failure
397 Association (HFA) of the European Society of Cardiology (ESC). European
398 Heart Journal. 2019;40: 3297–3317. doi:10.1093/eurheartj/ehz641

399 18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two
400 or more correlated receiver operating characteristic curves: a nonparametric
401 approach. Biometrics. 1988;44: 837–845.

402 19. Aung SM, Güler A, Güler Y, Huraibat A, Karabay CY, Akdemir I. Left atrial
403 strain in heart failure with preserved ejection fraction. Herz. 2017;42: 194–199.
404 doi:10.1007/s00059-016-4456-y

405 20. Obokata M, Negishi K, Kurosawa K, Arima H, Tateno R, Ui G, et al. Incremental
406 Diagnostic Value of LA Strain With Leg Lifts in Heart Failure With Preserved

407 Ejection Fraction. JACC: Cardiovascular Imaging. 2013;6: 749–758.
408 doi:10.1016/j.jcmg.2013.04.006

409 21. Ye Z, Miranda WR, Yeung DF, Kane GC, Oh JK. Left Atrial Strain in Evaluation
410 of Heart Failure with Preserved Ejection Fraction. Journal of the American
411 Society of Echocardiography. 2020;33: 1490–1499.
412 doi:10.1016/j.echo.2020.07.020

413 22. Dzhioeva O, Belyavskiy E. Diagnosis and Management of Patients with Heart
414 Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and
415 Recommendations. TCRM. 2020;Volume 16: 769–785.
416 doi:10.2147/TCRM.S207117

417 23. Braunauer K, Düngen H-D, Belyavskiy E, Aravind-Kumar R, Frydas A, Kropf
418 M, et al. Potential usefulness and clinical relevance of a novel left atrial filling
419 index to estimate left ventricular filling pressures in patients with preserved left
420 ventricular ejection fraction. European Heart Journal - Cardiovascular Imaging.
421 2020;21: 260–269. doi:10.1093/ehjci/jez272

422 24. Lin J, Ma H, Gao L, Wang Y, Wang J, Zhu Z, et al. Left atrial reservoir strain
423 combined with E/E' as a better single measure to predict elevated LV filling
424 pressures in patients with coronary artery disease. Cardiovasc Ultrasound.
425 2020;18: 11. doi:10.1186/s12947-020-00192-4

426 25. Choi KH, Yang JH, Seo JH, Hong D, Youn T, Joh HS, et al. Discriminative Role
427 of Invasive Left Heart Catheterization in Patients Suspected of Heart Failure

With Preserved Ejection Fraction. JAHA. 2023;12: e027581. doi:10.1161/JAHA.122.027581

Supplementary materials

Supplementary 1. Calculation of HFA-PEFF score

HFA-PEFF score				
Parameter	**Minor**		**Major**	
	Value	**Point**	**Value**	**Point**
Functional	Average E/e' 9 - 14 or GLS < 16%	1	Septal e' < 7 cm/s or lateral e' < 10 cm/s or Average E/e' ≥ 15 or TR velocity > 280 cm/s (PASP > 35 mmHg)	2
Morphological	LAVI 29 – 34 mL/m^2 or LVMI ≥ 115/95 g/m^2 (female/male) or RWT > 0.42 or LV wall thickness ≥	1	LAVI > 34mL/m^2 or LVMI ≥ 149/122 g/m^2 (female/male) and RWT > 0.42	2

	12 mm			
Biomarker (SR)	NT-proBNP 125 - 220 pg/mL or BNP 35 - 80 pg/mL	1	NT-proBNP > 220 pg/mL or BNP > 80 pg/mL	2
Biomarker (AF)	NT-proBNP 365 - 660 pg/mL or BNP 105 - 240 pg/mL	1	NT-proBNP > 660 pg/mL or BNP > 240 pg/mL	2

432 *Adapted from Heart Failure Association of the European Society of Cardiology*

433 Abbreviations: AF: atrial fibrillation; BNP: B-type natriuretic peptide; E: early
434 transmitral flow velocity; e': early diastolic mitral annular velocity; GLS: left
435 ventricular global longitudinal strain; HFA-PEFF: Heart Failure Association-PEFF;
436 LAVI: left atrial volume index; LV: left ventricle; LVMI: left ventricular mass index;
437 NT-proBNP: N-terminal pro-B-type natriuretic peptide; PASP: pulmonary artery
438 systolic pressure; RWT: relative wall thickness; SR: sinus rhythm; TRV: tricuspid
439 regurgitation velocity.


[%]
Strain [Longitudinal, PreA]
25
20
15
10
5
0
-5
-10
-15
-20
100
200
300
400
500
600
700
800
900
1,000
1,100
[ms]
Reservoir
Conduit
Contractile
Reference ED
Reference PreA
LASr_AC: 38.4 %
LAScd_AC: -24.0 %
LASct_AC: -14.4 %
Reference point: P wave

Fig1


HFA-PEFF
8
6
4
2
0
-2
***
Control
HFpEF
LASr (%)
40
30
20
10
0
***
Control
HFpEF
LAScd (%)
20
15
10
5
0
***
Control
HFpEF
LASct (%)
20
15
10
5
0
***
Control
HFpEF

Fig2

	NT-ProBNP	Septal e' velocity	Lateral e´velocity	E/A ratio	E/e' ratio	LAVI	TRV	GLS	HFA-PEFF	LASr	LAScd	LASct	LASr/LAVI	LASr/E/e'
NT-ProBNP	1.00	-0.04	-0.09	0.05	0.26	0.39	0.17	-0.26	0.42	-0.42	-0.35	-0.31	-0.40	-0.40
Septal e' velocity	-0.04	1.00	0.83	0.64	-0.39	-0.10	0.10	-0.02	0.07	-0.05	0.02	-0.11	0.01	0.23
Lateral e´velocity	-0.09	0.83	1.00	0.54	-0.49	-0.08	0.08	0.12	0.05	0.12	0.17	-0.02	0.10	0.39
E/A ratio	0.05	0.64	0.54	1.00	0.10	-0.03	0.37	-0.31	0.29	-0.30	-0.09	-0.39	-0.17	-0.21
E/e' ratio	0.26	-0.39	-0.49	0.10	1.00	0.19	0.41	-0.48	0.38	-0.54	-0.32	-0.48	-0.38	-0.67
LAVI	0.39	-0.10	-0.08	-0.03	0.19	1.00	0.23	-0.11	0.30	-0.24	-0.23	-0.14	-0.62	-0.27
TRV	0.17	0.10	0.08	0.37	0.41	0.23	1.00	-0.37	0.38	-0.67	-0.50	-0.54	-0.48	-0.50
GLS	-0.26	-0.02	0.12	-0.31	-0.48	-0.11	-0.37	1.00	-0.25	0.61	0.54	0.41	0.39	0.48
HFA-PEFF	0.42	0.07	0.05	0.29	0.38	0.30	0.38	-0.25	1.00	-0.46	-0.35	-0.38	-0.35	-0.42
LASr	-0.42	-0.05	0.12	-0.30	-0.54	-0.24	-0.67	0.61	-0.46	1.00	0.84	0.73	0.77	0.78
LAScd	-0.35	0.02	0.17	-0.09	-0.32	-0.23	-0.50	0.54	-0.35	0.84	1.00	0.25	0.71	0.59
LASct	-0.31	-0.11	-0.02	-0.39	-0.48	-0.14	-0.54	0.41	-0.38	0.73	0.25	1.00	0.50	0.54
LASr/LAVI	-0.40	0.01	0.10	-0.17	-0.38	-0.62	-0.48	0.39	-0.35	0.77	0.71	0.50	1.00	0.59
LASr/E/e'	-0.40	0.23	0.39	-0.21	-0.67	-0.27	-0.50	0.48	-0.42	0.78	0.59	0.54	0.59	1.00



Fig3


ROC of HFA-PEFF
ROC of LASr
ROC of LAScd
ROC of LASct
ROC of LAVI > 34 ml/m2
ROC of E/e' > 14
ROC of TR velocity > 2.8 m/s
ROC of Septal e' velocity < 7 cm/s
Sensitivity%
100% - Specificity%
0
20
40
60
80
100

Fig4


Sensitivity
100 - Specificity
0
20
40
60
80
100
HFA-PEFF
LASr
LAVI
TRV
E'e
e'
Comparison of AUCs
HFA-PEFF ~ LASr p = 0.062
HFA-PEFF ~ LAVI p < 0.001
HFA-PEFF ~ E/e' p < 0.001
HFA-PEFF ~ e' p < 0.001
HFA-PEFF ~ TRV p < 0.001
LASr ~ LAVI p < 0.001
LASr ~ E/e' p < 0.001

Fig5